568
Views & Citations10
Likes & Shares
Intensive care unit (ICU) sepsis in pediatric group of patients is a
common clinical practice primarily in the tertiary care settings. Emergence of
pathogens showing multidrug resistance pattern and causing ICU sepsis is
widespread and it poses a severe threat to physicians in terms of managing
their patients. At times, physicians get exposed to a pathogen they have never
encountered before. Burkholderia cepacia
infection in small children admitted in pediatric Intensive care unit (PICU) is
rare. This infection is common in patients with immunocompromised immunity and
underlying other debilitating disorders. We report a case of a 3 year and 06
month old female child who was diagnosed with ceftazidime-resistant Burkholderia cepacia in a PICU setting.
Keywords: Burkholderia, Ceftazidime, Drug resistant, Sepsis
INTRODUCTION
Burkholdria cepacia has emerged as an important
cause of hospital-acquired infections. The bacterium is known formerly as Pseudomonas cepacia, a gram negative
aerobic, glucose, non-fermenting, motile bacillus. Immunocompromised and
hospitalized patients are especially prone to this type of infection, leading
to severe bacteremia that may also result in death [1]. We present a case of a
3 year and 6 month old female child who was found to have signs of respiratory
tract infection followed by Burkholderia sepsis in a healthcare setting. We
faced lots of difficulties in treating the patient because the pathogen was
found to have resistance to ceftazidime which is usually considered as the
mainstay of treatment. Informed consent was obtained from the patient’s parents
to report this case.
CASE PRESENTATION
A 3 year and 6 month old
female child was brought to the paediatrics emergency with high grade fever
with convulsions and vomiting which was non-projectile and non-bilious. She was
apparently alright five days back when she developed fever which was of sudden
onset, high grade and not associated with chill and rigor. The fever was
subsiding with medication and recurring again. In this current episode the
fever was very high grade with convulsion and watery diarrhoea. She had
developed swelling of both lower limbs and abdominal distension for 3 days
which was gradual in onset.
On examination, the patient
was drowsy with no signs of meningeal irritation. She was looking sick with
presence of pallor and koilonychia. She had a respiratory rate of 25/min, a
blood pressure of 72/54 mm Hg and a pulse of 92/min, which was regular with
good volume and no radio-radial or radio-femoral delay. Systemic examination
was unremarkable, including the cardiovascular, gastrointestinal, and central
nervous systems. Respiratory system examination was positive for left lower
lobe crepitation.
Her laboratory
investigations revealed a total leukocyte count (TLC) of 26,000 cells per
microliter, hemoglobin- 10 g/dL, platelets- 2,24,000/µL, creatinine- 0.5 mg/dL,
blood urea- 86 mg/dL, serum albumin- 1.4 g/dL, total bilirubin- 0.2 mg/dL,
serum total protein- 3.4 g/dL, serum albumin- 1.4
She was put on piperacillin/tazobactam
empirically. Her respiratory distress worsened over the next day; a decision
was made to put her on mechanical ventilation because of acute respiratory
distress syndrome (ARDS). Chest X-ray showed bilateral infiltration. Before starting
the antibiotic, clinical samples like blood, urine, endotracheal tube aspirate
were sent for culture sensitivity using automated BacT Alert and Vitek-2
systems. Over the coming days, her leukocytosis worsened with a TLC up to
46,000/ µL and her condition became critical with deranged renal function
tests, liver functions tests, prothrombin time, and international normalized
ratio (INR). Her antibiotic was changed to meropenem. The blood culture and
endotracheal tube aspirate revealed the presence of ceftazidime resistant Burkholderia cepacia showing resistance
to other antibiotics like Colistin, Imipenem, Piperacillin/Tazobactam,
Ticarcillin/Clavulinic acid. As the isolated organism was sensitive to
Meropenem, Cefepime, Cefoperazone/sulbactam, Ciprofloxacin, Levofloxacin and
Trimethoprim/Sulfamethoxazole; the antibiotics were also changed to Meropenem.
On the ninth day, the patient was weaned off from the ventilator, as the signs
of sepsis were decreasing and she started with oral feeding. The antibiotic was
continued and she was discharged from the hospital on the 16th day.
She was advised to take oral Trimethoprim/Sulfamethoxazole with a regular
follow-up.
DISCUSSION
Burkholderia cepacia is an important nosocomial pathogen in
hospitalised patients, particularly those with prior broad-spectrum
antibacterial therapy. It causes infections that include bacteremia, urinary
tract infection, septic arthritis, peritonitis and respiratory tract infection
[2]. The respiratory tract is the most common route for an infection by Burkholderia cepacia, followed by
intravascular catheters [3]. Our patient appeared to have an infection in the
lungs accompanied by bacteremia. Burkholderia
cepacia can also be spread directly or indirectly from saliva or fomites of
patients with cystic fibrosis [4]. Risk of spread is higher by direct exchange
of respiratory secretions due to kissing or intimate social contact [5]. The
ability for Burkholderia species to thrive in the diverse range of environments
is testament to the fact that they can be considered as one of the most
versatile groups of gram-negative bacteria.
In the present case, the initial
symptoms of headache, convulsions and bilateral pitting edema with abdominal
distension can be explained by the septicemia. She was put on broad-spectrum
antibiotics and assisted ventilation. With the help of culture and sensitivity
testing, we were able to identify ceftazidime-resistant Burkholderia cepacia, but we were unable to identify the source of
infection. We thought of bacteremia due to hospital acquired infection as the
child was taking medication for the fever from several physicians on several
occasions. The drug of choice for the empirical treatment of Burkholderia cepacia bacteremia, in this
case, was meropenem as it also covered the other suspected causes of sepsis.
A similar case of an outbreak of
Burkholderia cepacia bacteremia in a
pediatric intensive care unit has been reported by Antony et al. from South
India [6]. The source of this outbreak was found to be contaminated distilled
water. Most of the infections caused by Burkholderia
cepacia are found in immunocompromised patients with opportunistic
infections and especially those with HIV infection and cystic fibrosis [7].
Ribonucleic acid (RNA)
sequencing revealed that the overexpression of resistance nodulation-division
(RND)-3 pump activity was attributed to mutations in the efflux pump regulator
gene. This can account for the mechanism of ceftazidime resistance in this
pathogen. In a recent study, it has been found that avibactam can restore the
activity of ceftazidime in ceftazidime-resistant Burkholderia species [8].
The success of this combination
of Avibactam with ceftazidime as a combination therapy is due to the ability of
avibactam to inhibit class A and C β-lactamases, including class A
carbapenemases (e.g. Klebsiella
pneumoniae carbapenemase (KPC)-2). This type of combination chemotherapy
may also be considered in ceftazidime resistant Burkholderia cepacia cases [9]. Ceftazidime-resistant Burkholderia cepacia; should also be
considered as an important differential for the sepsis patient who initially
presents with high grade fever with respiratory complaints; so that appropriate
investigations can be performed in time to improve the treatment outcome.
CONCLUSION
The emergence of Ceftazidime
resistant Burkholderia cepacia sepsis
in patients, especially in a healthcare setting, poses a significant threat to
our community. More and more cases infected with Burkholderia cepacia are being reported from our Institution and
this pathogen is becoming an increasingly common source of infection in
healthcare settings. Such type of pathogenic organism is also very difficult to
diagnose using conventional diagnostic methods. Availability of automated
culture and sensitivity system in the hospital set up has improved the
isolation and identification of such organisms. Getting the sensitivity pattern
with minimum inhibitory concentration (MIC) is an added advantage for such
pathogens. A high index of suspicion is required to diagnose and treat this
pathogen to prevent fatal outcomes related to its disease course.
1. Segonds
C, Chabanon G (2001) Burkholderia cepacia:
Dangers of a phytopathogen organism for patients with cystic fibrosis. Ann Biol
Clin (Paris) 59: 259-269.
2. Gautam
V, Singhal L, Ray P (2011) Burkholderia
cepacia complex: Beyond pseudomonas and acinetobacter. Indian J Med
Microbiol 29: 4-12.
3. Lu
DC, Chang SC, Chen YC (1997) Burkholderia
cepacia bacteremia: A retrospective analysis of 70 episodes. J Formos Med
Assoc 96: 972-978.
4. Martone
WJ, Tablan OC, Jarvis WR (1987) The epidemiology of nosocomial epidemic Pseudomonas cepacia infections. Eur J
Epidemiol 3: 222-232.
5. Govan
JR, Doherty CJ, Nelson JW (1993) Evidence for transmission of Pseudomonas cepacia by social contact in
cystic fibrosis. Lancet 342: 15-19.
6. Antony
B, Cherian EV, Boloor R, Shenoy KV (2016) A sporadic outbreak of Burkholderia cepacia complex bacteremia
in pediatric intensive care unit of a tertiary care hospital in coastal
Karnataka, South India. Indian J Pathol Microbiol 59: 197-199.
7. Coutinho
HM (2007) Burkholderia cepacia
complex: Virulence characteristics, importance and relationship with cystic
fibrosis. Indian J Med Sci 61: 422-429.
8. Papp-Wallace
KM, Becka SA, Zeiser ET (2017) Overcoming an extremely drug resistant (XDR)
pathogen: Avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates
from cystic fibrosis patients. ACS Infect Dis 3: 502-511.
9. Ehmann
DE, Jahić H, Ross PL (2013) Kinetics of avibactam inhibition against class A, C
and D β-lactamases. J Biol Chem 288: 27960-27971.